Trevi Therapeutics slips on $100 mln stock sale plans

Trevi Therapeutics

02/06/2025 21:20

**  Shares of Trevi Therapeutics TRVI.O down 3.6% in extended trading to $6.09 as co plans equity raise

** New Haven, Connecticut-based firm commences $100 mln stock offering

** Morgan Stanley. Leerink, Stifel and Cantor are jt bookrunners

** Before the bell on Mon, co announced positive topline results from Phase II trial of its therapy, Haduvio, for patients with a type of chronic cough, and said plans Phase III initiation in 2026

** With ~101.7 mln shares outstanding, co has about $680 market cap, per LSEG data

** TRVI closed down 3% at $6.32 on Mon, trimming YTD gain to 53%

 (Lance Tupper is a Reuters market analyst. The views expressed are his own)

 ((lance.tupper@tr.com 1-646-279-6380))